A Phase 1b/2 Study of YL-13027 Combined With Sintilimab in Patients With Advanced Solid Tumors
Clinical trial NCT05457517 · UNKNOWN
Trial details
- NCT number
- NCT05457517
- Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-24
- Primary completion
- 2024-06-01
- Enrollment
- 49
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.